IRIDEX Corporation (NASDAQ: IRIX), stock rose more than 36% in today’s premarket trading. The share price has been wild recently as investors appear eager to pounce on simple company news or fail to deliver any news at all.
However, on December 22, 2020, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases posted that MicroPulse Transscleral Laser Therapy, which is performed with the Cyclo G6 Laser System and MicroPulse P3 Device, proves clinically beneficial and is included in the European Glaucoma Society’s Terminology and Guidelines for Glaucoma.
The EGS guidelines can be used to standardize practice in the European Union on glaucoma diagnosis and management. On December 12-13, 2020, the new EGS guidelines were presented at the Society’s annual meeting.
The MicroPulse TLT procedure is a non-incisional procedure that significantly lowers intraocular pressure for patients with a broad range of glaucoma types and severity. Glaucoma can be treated through this procedure in cases of primary open-angle, closed-angle, and refractory glaucoma.
The MicroPulse TLT treatment is a repeatable treatment that can be applied in front of, during, or after glaucoma procedures. Over 140,000 patients have had this treatment in top ophthalmic hospitals throughout the world.